M&A / Deals Cumberland to sell drug portfolio to Apotex for $100m Pharmaceutical Business ReviewUnder the agreement, Apotex will acquire Cumberland's branded medicines for cash, subject to approval by Cumberland's shareholders.M&A / DealsRead full story pharminent April 24, 2026 (Last updated: April 24, 2026) Pharmaceutical Business Review Under the agreement, Apotex will acquire Cumberland’s branded medicines for cash, subject to approval by Cumberland’s shareholders. M&A / DealsRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA clears first genetic hearing loss gene therapyNext: Regeneron cuts White House pricing deal, offers new gene therapy for free Related Stories M&A / Deals Spero snaps up Innovent immunology drug in strategic pivot pharminent July 14, 2026 M&A / Deals AstraZeneca takes another China trip, picking Dizal’s lung cancer drug for up to $1.5B pharminent July 14, 2026 M&A / Deals Novartis and Chai Discovery collaborate on antibody identification pharminent July 14, 2026
